Back to Search Start Over

The influence of the gut microbiota on the bioavailability of oral drugs

Authors :
Ying Han
Xintong Zhang
Wei Huang
Zhonggao Gao
Mingji Jin
Source :
Acta Pharmaceutica Sinica B, Vol 11, Iss 7, Pp 1789-1812 (2021), Acta Pharmaceutica Sinica. B
Publication Year :
2021
Publisher :
Elsevier, 2021.

Abstract

Due to its safety, convenience, low cost and good compliance, oral administration attracts lots of attention. However, the efficacy of many oral drugs is limited to their unsatisfactory bioavailability in the gastrointestinal tract. One of the critical and most overlooked factors is the symbiotic gut microbiota that can modulate the bioavailability of oral drugs by participating in the biotransformation of oral drugs, influencing the drug transport process and altering some gastrointestinal properties. In this review, we summarized the existing research investigating the possible relationship between the gut microbiota and the bioavailability of oral drugs, which may provide great ideas and useful instructions for the design of novel drug delivery systems or the achievement of personalized medicine.<br />Graphical abstract The gut microbiota may influence the bioavailability of oral drugs by the microbial enzyme activity, affecting the drug transport or changing the gastrointestinal properties. This may provide us some advice on preventing the possible drug–drug interaction and offer us some useful strategies for the drug delivery system design.Image 1

Subjects

Subjects :
SLC, solute carrier
Bioavailability
AMI, amiodarone
MPA, mycophenolic acid
TLCA, taurolithocholate
ASP, amisulpride
RA, rheumatoid arthritis
Review
NRs, nitroreductases
MDR1, multidrug resistance gene 1
NaGC, sodium glycholate
MATEs, multidrug and toxin extrusion proteins
NMEs, new molecular entities
0302 clinical medicine
HFD, high fat diet
P-gp, P-glycoprotein
ACS, amphipathic chitosan derivative
Medicine
General Pharmacology, Toxicology and Pharmaceutics
LCA, lithocholic acid
0303 health sciences
Gastrointestinal tract
IBD, inflammatory bowel disease
pKa, dissociation constant
RBC, red blood cell
FA, folate
OATs, organic anion transporters
030220 oncology & carcinogenesis
MKC, monoketocholic acid
the GI tract, the gastrointestinal tract
AQP4, aquaporin 4
OCTNs, organic zwitterion/cation
T2D, type 2 diabetes
Gut microbiota
RM1-950
WHO, World Health Organization
03 medical and health sciences
EcN, Escherichia coli Nissle 1917
Drug Transport Process
BDEPT, the bacteria-directed enzyme prodrug therapy
BCS, biopharmaceutics classification system
NEC, necrotizing enterocolitis
DRPs, digoxin reduction products
NaDC, sodium deoxycholate
Probiotics
CPP, cell-penetrating peptide
OCTs, organic cation transporters
TDCA, taurodeoxycholate
cgr operon, cardiac glycoside reductase operon
RA - Rheumatoid arthritis
DCA, deoxycholic acid
AA, ascorbic acid
BBR, berberine
Personalized medicine
BDDCS, the biopharmaceutics drug disposition classification system
SSZ, sulfasalazine
UDC, ursodeoxycholic acid
PPIs, proton pump inhibitors
BCRP, breast cancer resistance protein
CS, chitosan
Gut flora
Bioinformatics
PD, Parkinson's disease
SLN, solid lipid nanoparticle
SGLT-1, sodium-coupled glucose transporter 1
Oral administration
MRP2, multidrug resistance-associated protein 2
FAO, Food and Agriculture Organization of the United Nations
SVCT-1/2, the sodium-dependent vitamin C transporter-1/2
an OTC drug, an over-the-counter drug
CA, cholic acid
biology
ABC, ATP-binding cassette
T1DM, type 1 diabetes mellitus
NSAIDs, non-steroidal anti-inflammatory drugs
AR, azoreductase
GCDC, glycochenodeoxycholate
Drug delivery
GL, glycyrrhizic acid
PT, pectin
LPS, lipopolysaccharide
TME, the tumor microenvironment
T1D, type 1 diabetes
TCDC, taurochenodeoxycholate
Oral drugs
MDR1a, multidrug resistance protein-1a
SCFAs, short-chain fatty acids
CDCA, chenodeoxycholic acid
030304 developmental biology
business.industry
dhBBR, dihydroberberine
biology.organism_classification
HTC, hematocrit
PWSDs, poorly water-soluble drugs
Colon-specific drug delivery system
stomatognathic diseases
SP, sulfapyridine
5-ASA, 5-aminosalicylic acid
BSH, bile salt hydrolase
TCA, taurocholate
Therapeutics. Pharmacology
business

Details

Language :
English
ISSN :
22113835
Volume :
11
Issue :
7
Database :
OpenAIRE
Journal :
Acta Pharmaceutica Sinica B
Accession number :
edsair.doi.dedup.....6d001e27a816f9de7d75ff16dd2143ec